Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis

Annals of the New York Academy of Sciences

Volumn 1229, Issue 1, 2011, Pages 124-132

  Kang, Nam Joo ^a   Jung, Sung Keun ^b   Lee, Ki Won ^c,d,e   Lee, Hyong Joo ^c,d  

^a Kyungpook National University   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Seoul National University   (South Korea)

^d Seoul National University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Chemoprevention; Myricetin; Signaling pathway; Skin carcinogenesis

Indexed keywords

CYCLOOXYGENASE 2; JANUS KINASE; MYRICETIN; PROTEIN KINASE B; PROTEIN KINASE FYN; RAF PROTEIN; STAT3 PROTEIN;

ANGIOGENESIS; ANTIAGING ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PHOTOAGING; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION;

EID: 79960813353     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06122.x     Document Type: Article

References (73)

1. Hertog, M.G. et al 1993. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342: 1007-1011.
2. Koeppen, B.H. & K. Herrmann 1977. Flavonoid glycosides and hydroxycinnamic acid esters of blackcurrants (Ribes nigrum). Phenolics of fruits 9. Z Lebensm Unters Forsch. 164: 263-268.
3. Mattivi, F. et al 2006. Metabolite profiling of grape: flavonols and anthocyanins. J. Agric. Food Chem. 54: 7692-7702.
4. Hertog, M.G. et al 1993. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 20: 21-29.
5. Griffiths, L.A. & G.E. Smith 1972. Metabolism of myricetin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem. J. 130: 141-151.
6. Formica, J.V. & W. Regelson 1995. Review of the biology of Quercetin and related bioflavonoids. Food Chem. Toxicol. 33: 1061-1080.
7. Luo, J.L. et al 2001. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res. 61: 8158-8163.
8. Newell, G.R. et al 1988. Incidence of cutaneous melanoma in the United States by histology with special reference to the face. Cancer Res. 48: 5036-5041.
9. Bode, A.M. & Z. Dong 2003. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci. STKE 167: 1-15.
10. Thomas, S.M. & J.S. Brugge 1997. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13: 513-609.
11. Matsumoto, T. et al 2002. Overexpression of a constitutively active form of c-Src in skin epidermis increases sensitivity to tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Mol. Carcinog. 33: 146-155.
12. Slaga, T.J. et al 1986. Critical genetic determinants and molecular events in multistage skin carcinogenesis. Symp. Fundam. Cancer Res. 39: 31-44.
13. Ayli, E.E. et al 2008. Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders. J. Cutan. Pathol. 35: 273-277.
14. Matsumoto, T. et al 2003. Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. Cancer Res. 63: 4819-4828.
15. Calautti, E. et al 1995. Fyn tyrosine kinase is involved in keratinocyte differentiation control. Genes Dev. 9: 2279-2291.
16. Sebolt-Leopold, J.S. & R. Herrera 2004. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4: 937-947.
17. Cobb, M.H. & E.J. Goldsmith 1995. How MAP kinases are regulated. J. Biol. Chem. 270: 14843-14846.
18. Sundaram, M. & M. Han 1995. The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell 83: 889-901.
19. Djavaheri-Mergny, M. & L. Dubertret 2001. UV-A-induced AP-1 activation requires the Raf/ERK pathway in human NCTC 2544 keratinocytes. Exp. Dermatol. 10: 204-210.
20. Rodriguez-Viciana, P., C. Sabatier & F. McCormick 2004. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell Biol. 24: 4943-4954.
21. Hoyos, B. et al 2002. Activation of c-Raf kinase by ultraviolet light. Regulation by retinoids. J. Biol. Chem. 277: 23949-23957.
22. Huntington, J.T. et al 2004. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem. 279: 33168-33176.
23. Rajagopalan, H. et al 2002. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.
24. Cho, H.J. et al 2007. Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms. Carcinogenesis 28: 1104-1110.
25. Whitmarsh, A.J. & R.J. Davis 2007. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26: 3172-3184.
26. Cantley, L.C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
27. Yuan, T.L. & L.C. Cantley 2008. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
28. Engelman, J.A., J. Luo & L.C. Cantley 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet 7: 606-619.
29. Samuels, Y. et al 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
30. Brunet, A. et al 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
31. Los, M. et al 2009. Switching Akt: from survival signaling to deadly response. Bioessays 31: 492-495.
32. Ozes, O.N. et al 1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
33. Imada, K. & W.J. Leonard 2000. The Jak-STAT pathway. Mol. Immunol. 37: 1-11.
34. Rane, S.G. & E.P. Reddy 2000. Janus kinases: components of multiple signaling pathways. Oncogene 19: 5662-5679.
35. Bowman, T. et al 2000. STATs in oncogenesis. Oncogene 19: 2474-2488.
36. Klampfer, L. 2006. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 6: 107-121.
37. Smith, W.L., D.L. DeWitt & R.M. Garavito 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69: 145-182.
38. Chen, W. et al 2001. Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene 20: 3921-3926.
39. Lee, J.L. et al 2003. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol. Appl. Pharmacol. 192: 294-306.
40. Fischer, S.M. et al 1999. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog. 25: 231-240.
41. Fischer, S.M. et al 2007. Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol. Carcinog. 46: 363-371.
42. Hanahan, D. & J. Folkman 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
43. Liekens, S., E. De Clercq & J. Neyts 2001. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61: 253-270.
44. Detmar, M. et al 1998. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111: 1-6.
45. Surazynski, A. et al 2008. Extracellular matrix and HIF-1 signaling: the role of prolidase. Int. J. Cancer 122: 1435-1440.
46. Handsley, M.M. & D.R. Edwards 2005. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer. 115: 849-860.
47. Forsythe, J.A. et al 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16: 4604-4613.
48. Iyer, N.V. et al 1998. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12: 149-162.
49. Ryan, H.E., J. Lo & R.S. Johnson 1998. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17: 3005-3015.
50. Strieter, R.M. 2005. Masters of angiogenesis. Nat. Med. 11: 925-927.
51. Pai, R. et al 2002. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8: 289-293.
52. Lee, K.M. et al 2007. Myricetin down-regulates phorbol ester-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking activation of nuclear factor kappa B. J. Agric. Food Chem. 55: 9678-9684.
53. Lee, K.W. et al 2007. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28: 1918-1927.
54. Kumamoto, T., M. Fujii & D.X. Hou 2009. Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett. 275: 17-26.
55. Kumamoto, T., M. Fujii & D.X. Hou 2009. Akt is a direct target for myricetin to inhibit cell transformation. Mol. Cell Biochem. 332: 33-41.
56. Kim, J.E. et al 2009. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem. Pharmacol. 77: 412-421.
57. Jung, S.K. et al 2008. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res. 68: 6021-6029.
58. Buening, M.K. et al 1978. Tumorigenicity of the optical enantiomers of the diastereomeric benzo[a]pyrene 7, 8-diol-9, 10-epoxides in newborn mice: exceptional activity of (+)-7beta, 8alpha-dihydroxy-9alpha, 10alpha-epoxy-7, 8, 9, 10-tetrahydrobenzo[a]pyrene. Proc. Natl. Acad. Sci. USA 75: 5358-5361.
59. Mukhtar, H. et al 1988. Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7, 12-dimethylbenz(a)anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, andN-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Res. 48: 2361-2365.
60. Ashurst, S.W. et al 1983. Formation of benzo(a)pyrene/DNA adducts and their relationship to tumor initiation in mouse epidermis. Cancer Res. 43: 1024-1029.
61. Das, M. et al 1987. Inhibition of epidermal xenobiotic metabolism in SENCAR mice by naturally occurring plant phenols. Cancer Res. 47: 760-766.
62. Ichihashi, M. et al 2003. UV-induced skin damage. Toxicology 189: 21-39.
63. Kim, W. et al 2010. Myricetin inhibits Akt survival signaling and induces Bad-mediated apoptosis in a low dose ultraviolet (UV)-B-irradiated HaCaT human immortalized keratinocytes. J. Radiat. Res. 51: 285-296.
64. Bergers, G. & L.E. Benjamin 2003. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3: 401-410.
65. Carmeliet, P. & R.K. Jain 2000. Angiogenesis in cancer and other diseases. Nature 407: 249-257.
66. Jung, S.K. et al 2010. Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo. Carcinogenesis 31: 911-917.
67. Smith, J.G., Jr. et al 1962. Alterations in human dermal connective tissue with age and chronic sun damage. J. Invest. Dermatol. 39: 347-350.
68. Chung, J.H. et al 2001. Modulation of skin collagen metabolism in aged and photoaged human skin in vivo. J. Invest. Dermatol. 117: 1218-1224.
69. Grewe, M. et al 1993. Analysis of the mechanism of ultraviolet (UV) B radiation-induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J. Invest. Dermatol. 101: 528-531.
70. Alonso-Fernandez, P. & M. De la Fuente 2011. Role of the immune system in aging and longevity. Curr. Aging Sci. Epub ahead of print.
71. Sim, G.S. et al 2007. Structure activity relationship of antioxidative property of flavonoids and inhibitory effect on matrix metalloproteinase activity in UVA-irradiated human dermal fibroblast. Arch. Pharm. Res. 30: 290-298.
72. Huang, J.H. et al 2010. Protective effects of myricetin against ultraviolet-B-induced damage in human keratinocytes. Toxicol. In Vitro. 24: 21-28.
73. Jung, S.K. et al 2010. Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem. Pharmacol. 79: 1455-1461.